ELDNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Eledon Pharmaceuticals, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$2.16+0.03 (+1.41%)

Close on Oct 19, 2026

Market cap: $245.44M
P/E (TTM): –
Dividend yield: –

Eledon Pharmaceuticals, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31
Cash & Equivalents	23	21	4.61	56	85	114	8.79	13	17	1.12	3.11	105	32	12	2.25
Short-Term Investments	111	120	46	0	–	–	–	–	–	–	–	–	–	–	–
Cash & Short-Term Investments	133	140	51	56	85	114	8.79	13	17	1.12	3.11	105	32	12	2.25
Prepaid Expenses & Other	2.35	3.55	5.03	3.11	3.51	1.44	1.18	1.30	1.70	0.03	3.21	2.26	0.43	–	–
Other Current Assets	0.01	0.10	0.09	0.03	0.03	0.04	0.05	0.04	0.02	0.03	–	–	–	–	–
Total Current Assets	136	144	56	60	88	116	9.97	14	19	1.15	67	108	32	–	–
Property, Plant & Equipment	–	–	–	–	–	–	0.01	0.01	0.03	0.03	0.49	0.03	0.03	–	–
Gross Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	0.23	0.65	0.09	0.07	–	–
Accumulated Depreciation	–	–	–	–	–	–	–	–	–	-0.13	-0.17	-0.06	-0.04	–	–
Operating Lease Right-of-Use Assets	0.61	0.93	0.37	0.74	0.77	0.14	0.32	–	–	–	–	–	–	–	–
Goodwill	–	–	0	0	49	49	–	1.87	1.87	–	–	–	–	–	–
Deferred Tax Assets	–	–	–	–	–	–	–	–	–	–	–	33	24	–	–
Other Long-Term Assets	0.32	0.36	0.19	0.15	0.40	0.38	0.64	0.87	–	0.02	0.05	–	–	–	–
Total Assets	169	177	89	93	171	197	11	17	21	1.20	68	108	32	–	–
Accounts Payable	3.63	5.83	0.97	2.20	1.81	1.37	0.33	0.69	0.42	0.34	1.21	0.77	0.01	–	–
Accrued Expenses	–	–	–	–	–	–	–	–	–	0.11	4.95	3.48	2.20	–	–
Current Portion of Leases	0.36	0.31	0.38	0.36	0.37	0.14	0.18	–	–	–	–	–	–	–	–
Total Current Liabilities	18	12	3.90	6.48	4.40	2.48	1.32	2.53	–	3.90	6.16	4.24	2.21	–	–
Long-Term Leases	0.28	0.64	0	0.38	0.40	–	0.14	–	–	–	–	–	–	–	–
Operating Lease Liabilities	0.64	0.95	0.38	0.75	0.77	0.14	0.32	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	2.19	2.18	1.75	1.75	1.75	4.11	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	–	–	–	–	–	–	–	–	–	–	0.09	–	–	–	–
Total Liabilities	32	59	82	8.61	6.55	6.59	1.47	2.53	1.44	3.90	6.25	4.24	2.21	–	–
Preferred Stock	–	–	–	–	–	–	–	–	–	0.02	–	0	0	–	–
Common Stock	0.08	0.06	0.02	0.01	0.01	0.02	0.00	0.01	0.01	0.00	0.02	0.02	–	–	–
Additional Paid-In Capital	482	418	271	287	279	271	67	56	47	11	193	190	7.79	–	–
Retained Earnings	-401	-356	-319	-203	-115	-80	-58	-42	-28	-14	-131	-86	-63	–	–
Comprehensive Income & Other	0.02	0.03	–	–	–	–	–	–	–	0.00	-0.06	–	–	–	–
Shareholders' Equity	81	62	-48	24	164	191	9.47	14	19	-2.70	2.78	104	-55	-40	-30
Total Equity	81	62	-48	24	164	191	9.47	14	19	-2.70	2.78	104	-55	-40	-30
Total Liabilities & Equity	169	177	89	93	171	197	11	17	21	1.20	68	108	32	–	–
Shares Outstanding(shares)	75	60	24	14	14	15	0.72	0.52	0.40	0.02	0.00	0.00	0.00	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -63.6%

Financial strength

Current ratio: 7.90
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 57.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 7.43
Dividend yield: –